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Abstract
Background: Chronic granulomatous disease (CGD) is a rare disorder of phagocytes in which
absence of superoxide and hydrogen peroxide production in phagocytes predisposes patients to
bacterial and fungal infections. The most common fungal infections in these patients are caused by
Aspergillus species.
Case presentation: Here, we describe Aspergillus osteomyelitis of the ribs and hepatic abscess in
a 5-year-old boy. The patient was successfully treated with Amphotericin B and INF-γ .
Conclusion: With respect to the high frequency of aspergillosis in the CGD patient, immune
deficiency should be investigated in patients with invasive aspergillosis. Moreover, using antifungal
drugs as prophylaxis can improve the quality of life in these patients.
Background
Chronic granulomatous disease (CGD) is a rare inherited
disorder of nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase complex of phagocytic cells resulting in
failure to generate reactive oxidants and the absence of a
respiratory burst [1]. The disease is characterized by recur-
rent or persistent intra-cellular bacterial and fungal infec-
tions. Approximately, the incidence of fungal infections in
CGD patients has been reported up to 20% of infections
[2]. Aspergillus spp are ubiquitous saprophytic fungi and
are considered as the major causative fungal agent in these
patients [2,3]. The spectrum of infection caused by
Aspergillus species varies from flu-like pneumonia to life-
threatening invasive aspergillosis [4]. The most common
form of the aspergillosis in CGD patients is Aspergillus
pneumonia which can be accompanied by dissemination
to the ribs, chest wall and soft tissues [1,2]. Here, we
describe a case of invasive aspergillosis in CGD patient
with hepatic abscesses and osteomyelitis.
Case Presentation
A 5-year-old male patient was admitted to Children Med-
ical Center (CMC) with inflammation and swelling in his
left mandible and wrist without a history of trauma. In the
past, he had suffered from several episodes of pneumonia
which started at the age of seven months. On admission,
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laboratory findings included erythrocyte sedimentation
rate (ESR) 84 mm/h, WBC count 12100/mm3 (61% neu-
trophils, 39% lymphocytes), hemoglobin 11.3 gr/dl and
thrombocyte 386000/mm3. As the CRP analysis dis-
played 20 mg/dl, cephalexin (150 mg/kg/day) was initi-
ated. In his roentgenogram, osteolytic lesions in the distal
metaphase of hand and maxillary bone were observed.
Considering history of several infections and multifocal
osteomyelitis, bone biopsy was performed and his
immune system function was evaluated. In the bone
biopsy, non-necrotizing granulomatoid lesions were seen.
The induration of purified protein derivative reaction was
10 mm diameter. Besides, HIV, hepatitis B surface antigen
(HBs), rheumatoid factor and brucella agglutination tests
were all negative. The serum IgG level was 1650 mg/dl
(normal: 441–1135 mg/dl). IgM and IgA were in high
normal range at 250 and 175 mg/dl, respectively. Because
no defect was found in his humeral and cellular immu-
nity, the phagocytic cells function was tested with a
nitroblue-tetrazolium (NBT) slide test. Based on his
hematological and immunological tests (NBT = 0), CGD
was considered as underlying disease in this case. Regard-
ing his NBT test, antibiotic therapy was changed from
cephalexin to co-trimoxazole (20 mg/kg/day, iv) plus
(along with) interferon-γ  (50 microgram/m2 every other
day). After two weeks of treatment, the patient's condition
improved and he was discharged with prescription of
both cephalexin (100 mg/kg/day) and co-trimoxazole (10
mg/kg/day) to be taken orally as prophylaxis.
The patient was readmitted to our center after eight
months with a tender mass in his right upper quadrant
(RUQ) (Fig 1). On admission, his major complaint was
severe dyspnea, a persistent cough and also chest and
abdominal pain in epigastric area which was started 10
days ago. He was placed on antibiotic therapy including
cephalexin (100 mg/kg/day). A computerized tomogra-
phy (CT) scan of the chest and abdomen was performed
which revealed the hypodense area in liver (Fig 2). Adja-
cent to this opacity, involvement of lower right ribs and
Subcutaneous swelling and granuloma formation in right upper quadrant Figure 1
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reaction to soft tissue were also observed, indicating ribs
osteomyelitis. After sonography guided drainage of the
above-mentioned hepatic abscess, a sample was sent to
the Mycology Department in Tehran University of Medi-
cal Sciences. The microscopic examination of clarified
specimen with KOH 10% indicated the branched, sep-
tated and dichotomous mycelia (Fig. 3). The remaining
specimen was also cultured on Brain Heart Infusion agar
(BHI), Sabouraud's dextrose agar (S) and Sabouraud's
containing 0.005% chloramphenicol (Sc). The S and Sc
culture media were incubated at 25°C and BHI at 37°C.
The colonies grew rapidly, attaining the diameter of 5 cm
within 5 days and their color was bluish green. Cello-
phane tape preparations and slide cultures demonstrated
septated, branched and hyaline hyphae with rough-
walled conidiophores and radiated conidial heads. Based
on these microscopic and macroscopic findings, Aspergil-
lus fumigatus was determined as causative agent in this
case. Deoxycholate Amphotericin B (1 mg/kg/day, iv),
interferon-γ  (50 microgeram/m2 every other day, sc) and
rifampicin (10 mg/kg/day) were administered with diag-
nosis of invasive aspergillosis. The only adverse event
observed during treatment was hypokalemia, which was
adjusted by administration of potassium chloride 15%.
One month after initiation of antifungal therapy, his fol-
low-up CT scan of the abdominal and thoracal region
demonstrated relative resolution of hepatic abscess. After
four weeks of intravenous treatment, the patient's clinical
condition improved. He was discharged upon his parents'
responsibility while continuing taking rifampicin (10 mg/
kg/day) for two more weeks as a treatment in addition to
co-trimoxazole (5 mg/kg/day) and itraconazole (4 mg/kg/
day) as long term prophylaxis.
Discussion
CGD is a rare inherited immune disorder whose preva-
lence is estimated to be about 1/1,100,000 – 1/1,300,000
individuals worldwide [1]. Similar to the presented case,
the most common form of CGD is X-linked recessive that
consists of about two thirds of cases and the rest are auto-
somal recessive [5].
In the absence of minimal oxidative metabolism in CGD
which can be ascertained easily using nitro blue tetrazo-
lium (NBT) slide test, other immune mechanisms are trig-
gered [6]. The relative evaluated immunoglobulin levels
in the above-mentioned case might be due to persistent
antigenic stimulation and it is a common phenomenon in
all chronic infections.
This defect is characterized by recurrent or persistent infec-
tions due to catalase-positive fungal and bacterial agents
despite aggressive antibiotic therapy [1,6]. The incidence
of aspergillosis in these patients has been reported to be
78% of all fungal infections [2]. Among Aspergillus spp,
Aspergillus fumigatus is considered to be the predominant
cause of invasive aspergillosis in CGD patients [1,7]. Pul-
monary aspergillosis has been reported in CGD patients
infected with Aspergillus fumigatus. As shown in this case,
Aspergillus might spread from lungs to the bones of tho-
racic wall and cause osteomyelitis [7-9]. Although
Aspergillus fumigatus is considered to be the most isolated
species, Aspergillus nidulans osteomyelitis is reported to
Computerized tomography showed a hypodense area in right  lobe of liver with peripheral enhancement Figure 2
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have a higher incidence and more mortality rate in these
patients [7,9].
The treatment of infections in CGD patients is not easy.
Since the underlying immunodeficiency is the most
important factor with respect to the outcome of treatment,
these patients should be treated either with
immunomudulative agents such as recombinant INF-γ  or
with stimulating factors [10]. Recently, on the basis of
cytochrome b (558) expression and NADPH oxidase
activity, three different sub-type of X-linked chronic gran-
ulomatous disease were described [11]. Therefore, thera-
peutic response to INF-γ  in this case and other X-linked
CGD patients might be elucidated. Besides, similar to
other systemic fungal infections, antifungal drugs such as
amphotericin B should be added to therapeutic regimen
of CGD patients with established invasive aspergillosis.
Our patient responded to the above-mentioned therapeu-
tic protocol and was discharged with long term anti-
microbial and immunomudulatory prophylactic treat-
ment as well as anti fungal drug [12] to enhance the qual-
ity of life and lessen the risk of re-infection.
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